Drug intelligence / Profile preview

nab-paclitaxel + apatinib + adebrelimab

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Oral

Overview

This combination therapy consists of nab-paclitaxel, apatinib, and adebrelimab. Nab-paclitaxel is a nanoparticle albumin-bound formulation of the cytotoxic agent paclitaxel, which functions as a microtubule-stabilizing agent to inhibit cell mitosis. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), thereby exerting anti-angiogenic effects. Adebrelimab is a humanized monoclonal antibody that targets programmed cell death 1 ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to restore anti-tumor immune responses. This triplet regimen is being evaluated in Phase 2 clinical trials by The First Affiliated Hospital of Xiamen University for the treatment of locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients who have previously progressed on immunotherapy.

Brand names: AbraxaneAiTanAiruika
Other names: Paclitaxel (Albumin-bound) + Apatinib + Adebrelimabnab-paclitaxel + apatinib mesylate + adebrelimabnab-paclitaxel-The First Affiliated Hospital of Xiamen University-gastric adenocarcinoma-gastroesophageal junction adenocarcinoma

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFR2 (Vascular endothelial growth factor receptor 2)CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on nab-paclitaxel + apatinib + adebrelimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nab-paclitaxel + apatinib + adebrelimab.

Explore the full profile